Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening
Guardant Health (Nasdaq: GH) is set to ring the Nasdaq opening bell on August 28, 2024, celebrating the launch of their Shield™ blood test for colorectal cancer screening. This FDA-approved test offers a more comfortable alternative for early cancer detection, potentially improving survival rates.
The event marks nearly six years since Guardant's IPO bell-ringing. Co-CEO AmirAli Talasaz emphasized the significance of this milestone for the company, liquid biopsy field, and patients. The ceremony will be broadcast live at 8:30 a.m. Eastern Time, followed by a Behind the Bell interview with management.
Guardant's team will be available in New York City on August 28-29 for media interviews and investor meetings, highlighting the company's commitment to advancing precision oncology.
Guardant Health (Nasdaq: GH) è pronta a suonare la campana di apertura del Nasdaq il 28 agosto 2024, celebrando il lancio del loro test del sangue Shield™ per lo screening del cancro colorettale. Questo test, approvato dalla FDA, offre un'alternativa più confortevole per la rilevazione precoce del cancro, con potenziali miglioramenti nei tassi di sopravvivenza.
L'evento segna quasi sei anni dal suono della campana in occasione dell'IPO di Guardant. Il Co-CEO AmirAli Talasaz ha sottolineato l'importanza di questo traguardo per l'azienda, il campo delle biopsie liquide e i pazienti. La cerimonia sarà trasmessa in diretta alle 8:30 ora orientale, seguita da un'intervista Behind the Bell con il management.
Il team di Guardant sarà disponibile a New York il 28-29 agosto per interviste con i media e incontri con gli investitori, evidenziando l'impegno dell'azienda verso l'avanzamento dell'oncologia di precisione.
Guardant Health (Nasdaq: GH) está preparando para tocar la campana de apertura del Nasdaq el 28 de agosto de 2024, celebrando el lanzamiento de su prueba de sangre Shield™ para la detección del cáncer colorrectal. Esta prueba, aprobada por la FDA, ofrece una alternativa más cómoda para la detección temprana del cáncer, lo que podría mejorar las tasas de supervivencia.
El evento marca casi seis años desde que Guardant hizo sonar la campana de su OPI. El Co-CEO AmirAli Talasaz enfatizó la importancia de este hito para la empresa, el campo de las biopsias líquidas y los pacientes. La ceremonia se transmitirá en vivo a las 8:30 a.m. hora del Este, seguida de una entrevista Behind the Bell con la dirección.
El equipo de Guardant estará disponible en Nueva York del 28 al 29 de agosto para entrevistas con los medios y reuniones con inversores, resaltando el compromiso de la empresa con el avance de la oncología de precisión.
Guardant Health (Nasdaq: GH)는 2024년 8월 28일에 나스닥 개장 종을 울릴 준비를 하고 있으며, 대장암 검진을 위한 Shield™ 혈액 검사의 출시를 기념합니다. 이 FDA 승인 검사는 조기 암 발견을 위한 더 편안한 대안을 제공하여 생존율을 향상시킬 가능성이 있습니다.
이 행사는 Guardant의 IPO 후 종을 울린지 거의 6년이 되는 것을 기념합니다. 공동 CEO AmirAli Talasaz는 이 이정표가 회사, 액체 생검 분야 및 환자들에게 얼마나 중요한지를 강조했습니다. 이 의식은 동부 표준시 기준으로 오전 8시 30분에 생중계되며, 이어서 경영진과의 Behind the Bell 인터뷰가 진행됩니다.
Guardant의 팀은 8월 28일부터 29일까지 뉴욕에서 기자 인터뷰와 투자자 회의를 위해 이용 가능하며, 정밀 종양학 발전에 대한 회사의 의지를 강조합니다.
Guardant Health (Nasdaq: GH) s'apprête à sonner la cloche d'ouverture du Nasdaq le 28 août 2024, célébrant le lancement de leur test sanguin Shield™ pour le dépistage du cancer colorectal. Ce test, approuvé par la FDA, offre une alternative plus confortable pour la détection précoce du cancer, ce qui pourrait améliorer les taux de survie.
L'événement marque presque six ans depuis la sonnerie de la cloche lors de l'introduction en bourse de Guardant. Le Co-CEO AmirAli Talasaz a souligné l'importance de cette étape pour l'entreprise, le domaine des biopsies liquides et les patients. La cérémonie sera diffusée en direct à 8h30 heure de l'Est, suivie d'une interview Behind the Bell avec la direction.
Équipe de Guardant sera disponible à New York le 28 et 29 août pour des interviews avec les médias et des réunions avec des investisseurs, soulignant l'engagement de l'entreprise envers l'avancement de l'oncologie de précision.
Guardant Health (Nasdaq: GH) wird am 28. August 2024 die Eröffnungsglocke der Nasdaq läuten und den Start ihres Shield™ Bluttests zur Früherkennung von Darmkrebs feiern. Dieser von der FDA genehmigte Test bietet eine komfortablere Alternative zur Früherkennung von Krebs, was potenziell die Überlebensraten verbessern könnte.
Die Veranstaltung markiert fast sechs Jahre seit dem Glockenläuten zur IPO von Guardant. Co-CEO AmirAli Talasaz betonte die Bedeutung dieses Meilensteins für das Unternehmen, den Bereich der Flüssigbiopsie und die Patienten. Die Zeremonie wird live um 8:30 Uhr Eastern Time übertragen, gefolgt von einem Behind the Bell-Interview mit dem Management.
Das Team von Guardant wird am 28. und 29. August in New York für Medieninterviews und Investorenmeetings zur Verfügung stehen und damit das Engagement des Unternehmens für fortschrittliche Präzisionsonkologie unterstreichen.
- None.
- None.
“We recently launched Shield, our FDA-approved blood-based screening test, marking a pivotal moment on our journey to conquer cancer with data. We are thrilled to commemorate this important milestone by ringing the Nasdaq bell, nearly six years after we first rang the bell for our IPO,” said AmirAli Talasaz, Guardant Health co-CEO. “Shield offers a more pleasant way to stay up to date with colorectal cancer screening and detect the disease early, when patients have the best chance of survival. This launch is a historic moment for Guardant, the liquid biopsy field, cancer screening, and most importantly, for patients. I’d like to thank our team for their hard work during the last 10 years to bring us here.”
The live broadcast of the Nasdaq Opening Bell ceremony will begin at 8:30 a.m. Eastern Time on Wednesday, August 28, 2024. To view the broadcast, visit: https://www.nasdaq.com/marketsite/bell-ringing-ceremony.
Management will also take part in a Behind the Bell interview from the Nasdaq MarketSite following the opening bell ceremony, which will be available at https://www.nasdaq.com/news-and-insights/behind-the-bell once published.
Company management will be in
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240822352380/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Melissa Marasco
press@guardanthealth.com
+1 650-647-3711
Source: Guardant Health, Inc.
FAQ
When is Guardant Health (GH) ringing the Nasdaq opening bell?
What is the Shield™ blood test by Guardant Health (GH)?
How long has it been since Guardant Health's (GH) IPO?
Where can I watch Guardant Health's (GH) Nasdaq opening bell ceremony?
